Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis

被引:20
|
作者
Qiu, Shiyuan [1 ,3 ]
Zhang, Hengci [2 ]
Yu, Sijie [3 ]
Yang, Qin [3 ]
Zhang, Gaofu [3 ]
Yang, Haiping [3 ]
Li, Qiu [3 ]
Wang, Mo [3 ]
机构
[1] Chongqing You You Baobei Womens & Childrens Hosp, Pediat Internal Med Dept, Chongqing, Peoples R China
[2] Guizhou Med Univ, Guiyang, Peoples R China
[3] Chongqing Med Univ, Dept Nephrol,Minist Educ,Key Lab Child Dev & Diso, Natl Clin Res Ctr Child Hlth & Disorders,China In, Childrens Hosp,Chongqing Key Lab Pediat, Chongqing, Peoples R China
关键词
Systemic lupus erythematosus; Lupus nephritis; Children; Prognosis; DISEASE-ACTIVITY STATE; ERYTHEMATOSUS; SLE; CLASSIFICATION; VALIDATION; REMISSION; EFFICACY; CRITERIA; CHILDREN; SAFETY;
D O I
10.1007/s00467-021-05164-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and factors affecting prognosis, to guide pLN management according to T2T strategy. Methods This single-center retrospective study studied 220 children diagnosed with LN from January 2012 to December 2018, with > 6-month follow-up data on 173 and complete data on 137 patients. Primary outcome was treatment failure (deterioration or no response) at the latest follow-up. Results The most common pLN manifestation was proteinuria (81.36%). Females presented more often with rash (P<0.001) and alopecia (P=0.026) than males. Class IV LN (33.33%) was the most common grade on kidney biopsy. Median follow-up was 27.20 months (IQR, 15.78-44.45 months). One-, 3-, and 5-year cumulative overall survival rates were 93.5%, 87.8%, and 86.5%, respectively. The 5-year cumulative kidney survival rate was 97.1%. Regarding initial therapy, efficacy of corticosteroids combined with immunosuppressive agents was significantly better than corticosteroids alone (P=0.010). Factors with P<0.05 in univariate analysis, including hypoalbuminemia, higher SCr at diagnosis, lower eGFR at diagnosis, anti-dsDNA positivity, heavy proteinuria, hypertension, nervous-system involvement, treatment non-compliance, and SLEDAI-2K score, were used for logistic regression analysis. Logistic regression analysis showed hypertension (OR=0.845, P=0.011), nervous-system involvement (OR=4.240, P=0.005), treatment non-compliance (OR=6.433, P=0.001), and lower estimated glomerular filtration rate at diagnosis (OR=1.020, P=0.021) affected prognosis. At end of follow-up, 34.31% achieved varying levels of remission, and 8.76% were in low disease activity state (LDAS). Conclusions pLN usually presented with proteinuria, and class IV LN was the dominant pathology. Hypertension, nervous-system involvement, treatment non-compliance, and lower eGFR at diagnosis were independent risk factors for poor prognosis of kidney outcomes. Compared with renal remission rate and cumulative overall survival rate, the proportion of targets achieved was not ideal, suggesting T2T strategy should be used to guide pLN management.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 50 条
  • [21] Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight
    Doria, A.
    Gatto, M.
    Iaccarino, L.
    Punzi, L.
    LUPUS, 2015, 24 (4-5) : 507 - 515
  • [22] Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs
    James Cheng-Chung Wei
    Drugs, 2014, 74 : 1091 - 1096
  • [23] Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
    Sanchez, Agner R. Parra
    Voskuyl, Alexandre E.
    van Vollenhoven, Ronald E.
    NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (03) : 146 - 157
  • [24] Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs
    Wei, James Cheng-Chung
    DRUGS, 2014, 74 (10) : 1091 - 1096
  • [25] Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?
    Morand, Eric F.
    Golder, Vera
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (10) : 1256 - 1258
  • [26] Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
    Agner R. Parra Sánchez
    Alexandre E. Voskuyl
    Ronald F. van Vollenhoven
    Nature Reviews Rheumatology, 2022, 18 : 146 - 157
  • [27] Editorial: Treat-to-target in systemic lupus erythematosus: cytokine transduction pathways in SLE
    Nozaki, Yuji
    Hao, Yanjie
    Barnas, Jennifer L.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Comment on "Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs"
    Wendling, Daniel
    Prati, Clement
    DRUGS, 2014, 74 (14) : 1715 - 1716
  • [29] Comment on “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”
    Daniel Wendling
    Clément Prati
    Drugs, 2014, 74 : 1715 - 1716
  • [30] Updated clinical practice treat-to-target guidelines for JIA management: the Egyptian College of Pediatric Rheumatology initiative
    El Miedany, Y.
    Salah, S.
    Lotfy, H.
    El Gaafary, M.
    Abdulhady, H.
    Salah, H.
    Nasef, S. I.
    Abd El-Latif, E.
    Farag, Y.
    Eissa, M.
    Esam Maher, S.
    Radwan, A.
    El-Shanawany, Amira T.
    Medhat, B. M.
    El Mikkawy, D.
    Mosa, D. M.
    El Deriny, G.
    Mortada, M.
    Osman, N. S.
    Fouad, N. A.
    Elkaraly, N. E.
    Mohamed, S. S.
    Tabra, S. A.
    Hassan, W. A.
    Amer, Y.
    Abu-Zaid, M. H.
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2022, 49 (01)